DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20190361

Study on association of serum lipoprotein(a) with coronary artery disease

P. Mohanraj, S. Sandhya

Abstract


Background: Most studies of lipid-lowering therapy for the prevention of coronary heart disease (CAD), focused on lowering low density lipoprotein cholesterol and non-HDL cholesterol. Other dyslipidemias, such as an elevated level of lipoprotein(a), also may promote atherosclerosis, establishment of relationship between lipoprotein(a) excess and risk for CAD, interventions directed toward altering these have only infrequently been evaluated in clinical trials. Objectives was to study the association of raised serum lipoprotein(a) in coronary heart disease.

Methods: This study was conducted in 50 patients of CAD and 50 people as control group. All patients underwent a standard clinical examination and a blood draw for a lipid profile and lipoprotein(a) assay. Pearson chi-square test was used to assess the statistical significance.

Results: Lipoprotein(a) value of more than 30 mg/dl is considered as elevated. In case group 19 patients (38%) were showed elevated lipoprotein(a) and in control group these were 9 patients (18%). p value is 0.026. It shows elevated lipoprotein(a) is statistically significant with the relative risk of 2.79.

Conclusions: The association of elevated lipoprotein(a) with CAD was statistically significant. Higher lipoprotein(a) levels were observed in patient with family history of premature CAD.


Keywords


Coronary heart disease, Dyslipidemias, Lipoprotein

Full Text:

PDF

References


Braunwald E, Zipes DP, Libby P. A Textbook of Cardiovascular Medicine, 6th ed. W.B. Saunders Co, USA; 2001:1010-1031.

Maron DJ, Ridker PM, Pearson TA, Grundy SM: Hurst’s the Heart, 10th ed. McGraw- Hill, USA; 2001:1131-1153.

Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol. 1996;27:978-90.

The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-46.

American Heart Association. Heart and Stroke Facts: Statistical Supplement. Dallas: American Heart Assoc; 1993-1995.

Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, et al. Declining serum total cholesterol levels among US adults. TheNational Health and Nutrition Examination Surveys. JAMA. 1993;269:3002-8.

Enas EA, Senthilkumar A. Role of Lipoprotien(a): Reality and Relevance. In: Gambhir, D. (ed.) Cardiology Update. CSI, New Delhi. 2002:8-25.

Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vas Biol. 1997;17:2783-92.

Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE, et al. Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterio Thromb Vas Biol. 2002 Jun 1;22(6):975-82.

Morrisett JD. The role of lipoprotein(a) in atherosclerosis. Curr Atheroscler Rep. 2000;2:243-50.

Grainger DJ, Krischenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle promoted by lipoprotein(a). Science. 1993;260:1655-8.

Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375-414.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004;24:e149-e161.

Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J. 1998;19:1355-64.

Budde T, Fechtrup C, Bosenberg E, Vielhauer C, Enbergs A, Schulte H, et al. Plasma Lp(a) levels correlate with number, severity,and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 1994;14:1730-6.

Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PWF, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem. 1999;45:1039-46.

Danesh J, Collins Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation. 2000;102:1082.

Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African Americans. Arterioscler Thromb Vas Biol. 1995;15:850-5.

Nishino M, Malloy MJ, Naya-Vigne J, Russell J, Kane JP, Redberg RF. Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women. J Am Coll Cardiol. 2000;35:314-20.

Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH. Human plasma lipoprotein [a]: structural properties. J Biol Chem. 1983;258:4582-9.

Loscalzo J. Lipoprotein (a): a unique risk factor for atherothrombotic disease. Arterioscler. 1990;10:672-9.

Schlaich MP, John S, Langenfeld MR, Lackner KJ, Schmitz G, Schmieder RE. Does lipoprotein(a) impair endothelial function? J Am Coll Cardiol. 1998;31:359-65.

Dangas G, Mehran R, Harpel PC, Sharma SK, Marcovina SM, Dube G, et al. Lipoprotein (a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol. 1998 Dec 1;32(7):2035-42.

American Association for Clinical Chemistry. NACB: emerging CV risk factors. Available at: https://www.aacc.org/science-and-practice/practice-guidelines/emerging-cv-risk-factors. Accessed October 31, 2007.

Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120:1012-5.

Chambless LE, Folsom AR, Sharrett AR, Sorlie P, Couper D, Szklo M, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol. 2003;56:880-90.

Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771-4.

Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9 -19.